Table 1.
Clinical, molecular, and biochemical features of IPAH patients.
| ID | Age (years) | Sex | PaO2 (mmHg) | 6 MWT (m) | PAP (mmHg) | CI (L/min/m2) | PVR (dyn/sec/cm2) | VR | PGC-1α RE | CYTC RE | SOD RE | TAS (mM) | GPX (nmol/min/mL) | Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HP1 | 45 | F | 67 | 595 | 48 | 1.3 | 12.4 | No | 2.87 | 2.45 | 4.12 | 0.21 | 70.23 | e + b |
| HP2 | 75 | M | 62 | 255 | 70 | 1.8 | 11 | No | 0.34 | 0.42 | 0.24 | 0.05 | 23.76 | a + s + i |
| HP3 | 34 | F | 85 | 554 | 35 | 2.8 | 6.2 | YES | 67.00 | 38.50 | 7.45 | 0.28 | 119.05 | n |
| HP4 | 58 | F | 70 | 380 | 48 | 2.2 | 12 | No | 6.07 | 5.47 | 2.29 | 0.19 | 67.89 | b + t |
| HP5 | 38 | F | 83 | 450 | 38 | 3.24 | 6.1 | YES | 8.96 | 6.95 | 26.77 | 0.15 | 91.27 | n |
| HP6 | 63 | F | 68 | 360 | 40 | 2.1 | 8.5 | No | 3.22 | 2.59 | 4.64 | 0.25 | 85.91 | i + b + s |
| HP7 | 64 | M | 60 | 240 | 53 | 2.3 | 7.7 | No | 0.34 | 0.48 | 0.14 | 0.04 | 20.22 | b + s + t |
| HP8 | 66 | M | 57 | 334 | 50 | 1.8 | 8.6 | No | 1.41 | 1.01 | 0.13 | 0.11 | 45.42 | s + i + b |
| HP9 | 60 | F | 58 | 120 | 49 | 1.1 | 18.9 | No | 0.34 | 0.08 | 0.13 | 0.02 | 24.26 | s + i + b |
| HP10 | 55 | F | 63 | 320 | 31 | 2.5 | 7.5 | YES | 7.76 | 8.34 | 3.47 | 0.22 | 90.85 | b + s |
| HP11 | 48 | F | 62 | 534 | 59 | 1.4 | 13.6 | No | 0.33 | 0.36 | 0.17 | 0.06 | 19.21 | e + s + b |
| HP12 | 72 | F | 60 | 280 | 65 | 2.2 | 12.5 | No | 0.22 | 0.21 | 0.50 | 0.01 | 14.34 | i + b |
PaO2: partial pressure of oxygen in arterial blood, 6MWT: 6-minute walk test, PAP: pulmonary arterial pressure, CI: cardiac index, PVR: pulmonary vascular resistance, VR: vasoreactivity, PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-α, RE: relative mRNA expression, CYTC: cytochrome c, SOD: superoxide dismutase, TAS: total antioxidant status, GPX: glutathione peroxidase, e: epoprostenol, si: sildenafil, i: iloprost, b: bosentan, t: treprostinil, and n: nifedipine.